Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review 50th Annual Meeting of the Midwest-Surgical-Association Bruzoni, M., Parikh, P., Celis, R., Are, C., Ly, Q. P., Meza, J. L., Sasson, A. R. EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC. 2009: 376–80

Abstract

Pancreatic nonfunctioning neuroendocrine tumors (PNFNETs) are an uncommon malignancy and often present with metastatic disease. There is a lack of information on the management of the primary tumor in patients who present with unresectable synchronous hepatic metastases.A retrospective review (2001-2008) of PNFNETs was conducted. Patients were divided into 3 groups: PNFNET without evidence of hepatic metastasis (group A), PNFNET with metastatic disease involving less than 50% of the liver (group B), and PNFNET with metastatic disease involving more than 50% of the liver (group C). Clinical data and outcomes were analyzed.Thirty-five patients with PNFNET were identified (group A = 15, group B = 11, group C = 9). Resection of the pancreatic tumor was performed in 26 patients. With a mean follow-up period of 30 months, death from disease progression occurred in 1 patient in group A, none in group B, and in 7 in group C.In selected patients, resection of the primary pancreatic tumor even in the setting of unresectable but limited hepatic metastases may be indicated.

View details for DOI 10.1016/j.amjsurg.2008.11.005

View details for Web of Science ID 000264277400037

View details for PubMedID 19245918